3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
von Hippel-Lindau Disease
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Carcinoma, Renal Cell
1
Adenoma, Islet Cell
1
Interventions
Everolimus
2
trifluridine tipiracil drug combination
1
surufatinib
1
pegfilgrastim
1
pasireotide
1
gallium Ga 68 dotatate
1
fosbretabulin
1
entinostat
1
dactolisib
1
belzutifan
1
Temozolomide
1
TH 302
1
Surveys and Questionnaires
1
Sunitinib
1
Photochemotherapy
1
Nivolumab
1
Filgrastim
1
Fentanyl
1
Dihematoporphyrin Ether
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
belzutifan
×
Endocrine
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled